Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors
April 18 2018 - 8:30AM
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in
the development of restorative cell therapies (RCTs) that may offer
rapid-onset pain relief and restored function, today announced the
appointment of Susan Washer to its Board of Directors.
“Having known and worked with Sue for over 15
years, we are extremely pleased to welcome her to Histogenics’
Board of Directors,” stated Garheng Kong, M.D., Ph.D., Chairman of
the Board of Directors of Histogenics. “We believe Sue’s
experience in the growing area of cell and gene therapies combined
with her expertise in the development of novel gene therapies make
her an excellent choice for the Histogenics Board of
Directors.”
“The Histogenics restorative cell therapy
platform and the NeoCart product opportunity are compelling for
patients and clinicians, and I’m excited to be joining the Board of
Directors,” noted Sue Washer, President & Chief Executive
Officer of Applied Genetic Technologies Corporation (AGTC).
“I look forward to contributing to the growth of Histogenics as it
prepares for potential FDA submissions and commercialization and
continues to broaden its product platform both internationally and
in other potential therapeutic applications.”
Ms. Washer is the President and Chief Executive
Officer of AGTC, where she has served in such capacity since March
2002 and as a member of its board of directors since November 2003.
Ms. Washer was also AGTC’s Chief Operating Officer from October
2001 to March 2002. From June 1994 to October 2001, Ms. Washer led
two entrepreneurial firms including serving as president and CEO of
Scenic Productions and as the Founding Executive Director and then
Business Advisor for the North Florida Technology Innovation
Center, a public-private organization financing and providing
services to entrepreneurial companies licensing STEM based
technology from Florida universities. Ms. Washer currently
serves on the board of directors of Biotechnology Innovation
Organization (BIO) and the Alliance for Regenerative Medicine.
Previously, Ms. Washer served as chairman of the BioFlorida board
and the Southeast BIO board and continues her involvement with both
organizations as a member of their respective boards.
From October 1983 to June 1994, Ms. Washer
served in various research and pharmaceutical management positions
with Abbott Laboratories and Eli Lilly and Company. Ms. Washer
received a B.S. in biochemistry from Michigan State University and
an M.B.A. from the University of Florida.
About Histogenics
Corporation
Histogenics (Nasdaq:HSGX) is a leader in the
development of restorative cell therapies that may offer
rapid-onset pain relief and restored function. Histogenics’ lead
investigational product, NeoCart, is designed to rebuild a
patient’s own knee cartilage to treat pain at the source and
potentially prevent a patient’s progression to osteoarthritis.
NeoCart is one of the most rigorously studied restorative cell
therapies for orthopedic use. Histogenics recently completed
enrollment of its NeoCart Phase 3 clinical trial and expects to
report top-line, one-year superiority data in the third quarter of
2018. NeoCart is designed to perform like articular hyaline
cartilage at the time of treatment, and as a result, may provide
patients with more rapid pain relief and accelerated recovery as
compared to the current standard of care. Histogenics’ technology
platform has the potential to be used for a broad range of
additional restorative cell therapy indications. For more
information on Histogenics and NeoCart, please visit
www.histogenics.com.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Apr 2023 to Apr 2024